Wells Fargo & Company Relmada Therapeutics, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
1 transactions
Others Institutions Holding RLMD
# of Institutions
86Shares Held
13.5MCall Options Held
99KPut Options Held
28.2K-
Vanguard Group Inc Valley Forge, PA1.26MShares$4.27 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.23MShares$4.2 Million0.12% of portfolio
-
Vestal Point Capital, LP New York, NY1.2MShares$4.08 Million0.27% of portfolio
-
Acadian Asset Management LLC Boston, MA1.19MShares$4.06 Million0.01% of portfolio
-
Franklin Resources Inc San Mateo, CA1.01MShares$3.44 Million0.0% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $97.3M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...